Kornimate/medical-research-clean huggingface dataset:
cavatermtm vs tcre in women with dub

Conditions: Dysfunctional Uterine Bleeding

Summary: the purpose of study is to compare the treatment success in the study groups.

study success will be defined as reduction of uterine bleeding evaluated by number of patients obtaining amenorrhea, hypomenorrhea or eumenorrhea quantified by pblac\<75.

Eligibility criteria:
inclusion criteria: * willingness and adequate mental capacity to sign written, informed consent * willingness to adhere to study plan regarding control visits and recording of pblac * \> 30 years old * pre-menopausal as determined by fsh ≤30 * agree not to use hormonal contraception or any other intervention for bleeding during study * suitable for local and/or general anesthesia * a minimum pblac score of ≥ 150 for three months prior to study enrollment; or pblac score 150 for one month for women who 1) had at least 3 (documented) prior months of failed medical therapy; 2) had a contraindication to medical therapy; or 3) refused medical therapy * uterine cavity sound measurement ≥ 4 cm and ≤ 10 cm. exclusion criteria: * presence of bacteriaemia, sepsis, or other active systemic infection * active pelvic inflammatory disease * clotting defects or bleeding disorders * unwillingness to use a non-hormonal birth control post-ablation * desire for future fertility * abnormal cavity as confirmed by hysteroscopy, transvaginal ultrasound or hsg e.g. large fibroids, septum etc. small submucosal fibroids defined as \< 2 cm are in this context not considered abnormal. * any condition leading to possible uterine wall weakness with total wall thickness \< 15 mm e.g. at c.section, postmyomectomy scars etc. in case of uniform uterine wall the wall thickness at the fundus should be measured. * premalignant or malignant uterine condition within the last five years as confirmed by histology * pregnancy * cervical length \> 6 cm. * uterine cavity \>30 ml defined as balloon can be filled with 30ml glucose solution without reaching the target pressure of 240 mmhg. (these patients may still be treated as planned but will be withdrawn from the study and their data will be analysed separately. the patients will be recorded as screening failures). * previous ablation or subtotal hysterectomy

Keywords: menorrhagia dysfunctional uterine bleeding endometrial ablation
innovative modalities for restoring upper limb function post stroke

Conditions: Cerebrovascular Accident

Summary: purpose. after stroke many patients are unable to engage in normal upper limb functional activities, which may restrict them from participation in meaningful life roles. for many, conventional rehabilitation does not restore upper limb function to a useful level. the purpose of this research is to investigate the benefits of three promising motor learning interventions: focused intensive, motor learning (fiml); 2) robotics and motor learning (rob-ml); and 3) functional neuromuscular stimulation and motor learning (fns-ml).


Eligibility criteria:
inclusion criteria: * \>1 year post stroke no acute, uncontrolled medical condition single stroke exclusion criteria: * pacemaker other neurological condition more than one stroke

Keywords: stroke electric stimulation robotics motor learning
evaluation of sit-to-stand test in patients with cystic fibrosis and matched controls.

Conditions: Cystic Fibrosis

Summary: introduction: in recent years, since the discovery of the cystic fibrosis (cf) transmembrane conductance regulator gene in human skeletal muscle, there appears to be growing interest in the measurement of muscle function in cf. one of the most used test in other chronic pulmonary diseases is the sit-to-stand test (sts) which consists of simply getting up from a chair. although the main result of the sts test is the time developed during the task, the velocity and power generated during the task are considered very important variables to detect the functional decline. however, from our knowledge, no study has previously analyzed the differences in time, velocity and muscle power developed during the sts test in patients with cf and their respective healthy controls. objectives: to compare the values gained from handgrip strength, walking speed and sts test (time, velocity, and muscle power) in a group of patients with cf and their respective healthy controls, and to analyze if these differences (if any) are associated with lung function in patients with cf. methods: cross-sectional study with a sample of 60 participants (30 patients diagnosed with cf and 30 healthy subjects) between 18-65 years old. the sts test will be measured through slow-motion video recording with a smartphone device (240 images per second) which will report the time, velocity and power generated during the test. walking speed and handgrip strength will be also measured. additionally, the relationship between the variables obtained during the test and the lung function of patients with cf will be analized.


Eligibility criteria:
inclusion criteria: * patients with cystic fibrosis clinically stable; without experience on endurance or resistance training; no receiving long-term oxygen therapy. * healthy matched controls; without experience on endurance or resistance training. exclusion criteria: * using psychotropic medications; concomitant neurological, cardiovascular, metabolic, rheumatic or vestibular diseases; physical disabilities that impaired locomotion or chair rise; orthopedic problems; or a history of musculoskeletal system operations.

Keywords: cystic fibrosis sit-to-stand lung function handgrip walking speed power velocity gait speed chair rise
fpt155 in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this study is a phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of fpt155 as monotherapy in patients with advanced solid tumors.

this phase 1 study is comprised of dose escalation and cohort expansions for fpt155 monotherapy and for fpt155 in combination with pembrolizumab. monotherapy dose escalation is designed with initial accelerated titration followed by a standard 3+3 dose escalation; combination dose escalation uses a standard 3+3 design. patients will remain on study treatment until progression of disease, unacceptable toxicity, or other specified reason for discontinuation.

Eligibility criteria:
inclusion criteria: * histologically confirmed solid tumors (except primary central nervous system tumors). for patients enrolled for treatment with fpt155+pembrolizumab: histologically confirmed non-small cell lung cancer not eligible for curative therapy. * disease that is unresectable, locally advanced, or metastatic and has progressed following all standard treatments or is not appropriate for standard treatments * all patients must have at least one measurable lesion at baseline according to recist v1.1 * availability of archival tumor tissue and consent to provide archival tumor for retrospective biomarker analysis, or consent to undergo a fresh tumor biopsy during screening * for patients participating in cohort expansions: consent to undergo a mandatory fresh tumor biopsy during screening and on treatment * ecog performance status of 0 or 1 * prior radiotherapy must be completed at least 2 weeks before first dose of study treatment administration. no radiopharmaceuticals (eg, strontium, samarium) within 8 weeks before first dose of study treatment administration. * prior surgery that requires general anesthesia must be completed at least 14 days before first dose of study treatment * adequate bone marrow, liver and kidney function exclusion criteria: * uncontrolled or significant cardiac disease * any uncontrolled medical condition or psychiatric disorder including infection, autoimmune disease, bleeding disorder or symptomatic involvement of the central nervous system * treatment with any anti-cancer therapy or participation in another investigational drug or biologics trial within 28 days or ≤ 5 half-lives (whichever is shorter) * patients who discontinue prior immune-modulating therapies (including regimens containing an immune agonist or a pd-l1/pd-1 antagonist) due to toxicity or have received treatment within 5 half lives or 90 days * pregnancy or breastfeeding * for patients participating in cohort expansion: prior treatment with a ctla-4 antagonist, including ipilimumab and tremelimumab
study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (ad)

Conditions: Autistic Disorder; Behavioral Symptoms

Summary: this study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. most patients enrolled in this study will have participated in a short-term study with aripiprazole (cn138-178 \[nct00332241\] or cn138-179 \[nct00337571\]).


Eligibility criteria:
inclusion criteria - rollover: * completed 8 weeks of treatment in one of the following double-blind clinical trials: cn138-178 \[nct00332241\] or cn138-179 \[nct00337571\] * no significant protocol violations and sufficient medical justification to continue on open-label treatment with aripiprazole inclusion criteria - de novo: * meets current diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv tr) diagnostic criteria for ad and demonstrates serious behavioral problems - diagnosis confirmed by autism diagnostic interview-revised (adi-r) or the patient meets the current diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv tr) diagnostic criteria for ad and has a history of behavioral problems that are currently being treated with psychotropic medication * mental age of at least 18 months * male or female 6 to 17 years of age, inclusive, at the time of enrollment exclusion criteria: * patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each * patients previously treated and not responding to aripiprazole treatment * the patient is currently diagnosed with another disorder on the autism spectrum, including pervasive developmental disorder-not otherwise specified (pdd-nos), asperger's disorder, rett's disorder, fragile-x syndrome or childhood disintegrative disorder * current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression * a seizure in the past year * history of severe head trauma or stroke * non-pharmacologic therapy (e.g. psychotherapy, behavior modification) should be stable prior to screening and consistent throughout the study

Keywords: serious behavioral problems in children and adolescents with ad behavioral problems
magnesium treatment of inflammation in disorders of glucose homeostasis

Conditions: Non-Insulin Dependent Diabetes Mellitus

Summary: in most diabetic patients where low blood magnesium levels occur the important depletion of cellular levels is usually not measured. this study will measure both blood and oral mucosal cell magnesium levels before and after 3 months of supplementation with magnesium tablets (the recommended dietary amount of 336 milligrams per day). these magnesium levels will be correlated with blood levels of indicators of inflammation (eg c reactive protein) to see whether the cellular levels are more reliable than blood levels of magnesium for appropriate treatment of magnesium deficiency in diabetic patients.

the anti-inflammatory effects of oral magnesium (mg) supplementation of diabetic and metabolic syndrome patients with low serum mg levels have been studied with increased interest in recent years. however, serum magnesium levels only represent less than one percent of total body magnesium; whereas cellular deficiency of mg is a more reliable parameter to assess repletion of this essential mineral for correlation with indices of inflammation. the proposed research will compare the efficacy of a 3 month period of treatment with oral mg of diabetic patients selected for elevations of crp, tnfα and other markers of inflammation on cellular and serum levels of mg. we anticipate that 50 hypomagnesemic diabetic patients will be selected for 3 months of supplementation with 336 mg of mg lactate tablets. the repletion of serum and oral epithelial cell mg levels will be correlated with responses of crp, tnfα, substance p, hgbaic and oxidative/nitrosative (ros/rns) stress parameters before and after treatment. individuals will be selected from the dasman diabetes institute in kuwait. with completion of these analyses, a collaborative manuscript with joint authorship will be prepared and submitted for publication.

Eligibility criteria:
inclusion criteria: * have documented hypomagnesemia (serum levels ≤ 1.8 mg/dl or 0.74mmol/l); * be between 20-70 years of age at the time of randomization * have hyperglycemia due to niddm metabolic syndrome or obesity * have at least one abnormal indicator of inflammation (e.g. elevated crp, tnf-α) * have no active infection exclusion criteria: * currently have significant gastrointestinal disorders (e.g. chronic diarrhea); * have impaired renal function, defined as egfr \ 1.3 mg/dl; * are current being treated for hypertension (e.g. ace inhibitors and diuretics), heart block (e.g. ekg evidence of left bundle branch block) or heart failure (e.g. treated with aldosterone antagonists); * are currently pregnant; * have chronic inflammatory disorders (e.g. psoriasis); * have used of mg supplements and mg-rich mineral water within 6 months;

Keywords: hypomagnesemia, cellular mg, inflammation, diabetes mellitus
ctdna detection of mrd in predicting postoperative recurrence in biliary tract cancers：a multicenter prospective trial

Conditions: Biliary Tract Cancer

Summary: a substantial proporation of patients with biliary tract malignancies still experience disease recurrence after curative resection. ctdna-based minimal residual disease (mrd) method has been widely used to monitor postoperative recurrence in solid cancers, but few studies have been reported in biliary tract cancers. the present clinical trial aims to elucidate the correlation between the postoperative ctdna status and the prognosis of patients with biliary tract cancers, and evaluate whether ctdna could better predict patients' recurrence and guide clinical practice.


Eligibility criteria:
inclusion criteria: 1. male or female ≥ 18 years of age on the day of signing informed consent. 2. clinically diagnosed as btc before surgery and confirmed by pathology after surgery. 3. stage i-iii tumor according to the uicc/ajcc tnm staging system (8th edition in 2017), meeting the indications for radical surgery and are planned to undergo radical treatment. those who do not undergo radical surgery will be excluded. 4. patients must have a performance status of ≤1 on the ecog performance scale. 5. patients must have survival of \> 6 months after surgery 6. serological tumor indicators (cea, ca19-9) and imaging data ( ct and/or mri, pet-ct) were complete. 7. blood biochemical indicators meet surgical standards 8. written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study. exclusion criteria: 1. patients with recurrent biliary tract tumors 2. patients with hepatobiliary mixed tumors 3. patients with malignant tumors of other organs that have not been cured before. 4. history of organ transplant or allogeneic stem cell transplant 5. patients with severe infections that are active or poorly controlled clinically 6. patients who are cognitively impaired or with known psychiatric disorders, and/or substance abuse 7. pregnant or lactating women 8. failed to sign informed consent 9. other conditions that researchers judged inappropriate for inclusion

Keywords: cholangiocarcinoma ctdna minimal residual disease (mrd)
mobile monitoring of fracture healing

Conditions: Tibial Fractures

Summary: the objective of this study is to develop methods for using forces measured on circular external fixators to predict the state of individual patient's healing of severe tibial fractures and defects.

patients receiving external fixators for tibial fractures and defects will be recruited. normal struts on the device will be substituted with similar but instrumented struts which enable force measurement. during clinical visits, forces in the fixator, plus foot forces, will be measured during ambulation. changes in force measurements across treatment and bone healing will be analyzed. severe fractures in the lower limb are associated with high energy trauma in both civilian and military patients,and are sometimes treated with external fixation devices to stabilize the bone until healing has occurred. the devices are kept on the patient for up to a year or more at significant cost, intrusiveness, and risk of infection. the clinician must decide when to remove the device such that adequate healing has occurred and the bone will not re-fracture, but healing rates are variable and x-rays can be misleading. the clinician must also identify when a patient is starting to progress poorly and an early revision surgery is needed to prevent further complications. the investigators' goal is to develop novel approaches for instrumenting and collecting mechanical data from orthopaedic braces and devices, and identifying new methodologies for interpreting this large volume of functional data for optimizing personalized treatment. the present study is focused on external fixators. strain gauges will be adhered to the fixators so that fixator forces can be measured during clinical visits. in this pilot study the investigators will develop methods to predict healing based on these measured forces.

Eligibility criteria:
inclusion criteria: 1. 18 to 80 years of age 2. patients scheduled to undergo or currently undergoing treatment at hershey medical center for tibia fracture and/or defect using a circular external fixator including ilizarov and taylor spatial frame types. 3. ability to perform study procedures including ambulation (with assistance device if needed) exclusion criteria: 1. external fixator design that cannot be suitably instrumented for force measurements due to space constraints or other issues 2. axially stable fracture 3. inability to understand english 4. inability to provide informed consent 5. difficulty maintaining follow-up
effect of a third covid-19 booster among health care workers

Conditions: COVID-19 Vaccines

Summary: a new wave of covid-19 infections, mainly caused by the omicron/ delta variant, has been sweeping the globe since the start of 2022. in response, the administration of a third dose of covid-19 vaccine was considered to address potential waning immunity over time and reduced effectiveness against the omicron/ delta variant. the pandemic also resulted in many infections among health care workers (hcws) and their households. in this study, a retrospective analysis would perform on risk of covid-19 infection and their outcome in relation to their covid-19 vaccination history by using the data repository from one of the hong kong private hospitals. hcws were required to submit a standardized online self-declaration form for report of 1) demographic of the hcws, 2) symptoms related history and 3) covid-19 exposure history once they were covid-19 confirmed by rapid antigen test against covid-19 and/or polymerase chain reaction (pcr) test for covid-19. subsequent follow up such as contact tracing, covid-19 pcr testing results of these hcws and status of return to work were captured by the infection control team in a systematic manner.


Eligibility criteria:
inclusion criteria: * all full time staff members of the private hospital exclusion criteria: * history of covid-19 before 2022
predictors of recurrence in bipolar disorder in spain

Conditions: Bipolar Disorder

Summary: observational, prospective (1 year follow up), multicenter, non-interventional open label study in order to assess the factors that predict onset of mood disorders episodes (depression, mania, hypomania and mixed) in stabilized patients with bipolar disorder i or ii in spain. other objectives are 1. to describe the clinical course of illness in a cohort of patients with tb i or ii: duration, severity, polarity and seasonality 2. to describe clinical and functional situation of patients during the different phases, evaluating prognostic meaning of subsyndromal symptoms 3. to evaluate the economical impact on health service of these patients (hospitalization, primary care, treatments...). target population is ambulatory bipolar i and ii patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment. the primary endpoint is the onset of mood disorders episodes (depression, mania, hypomania and mixed) during the follow-up period and evaluation of which factors predict onset of mood episodes


Eligibility criteria:
inclusion criteria: * diagnosed of bipolar disorder i or ii (dsm-iv-tr) * patients stabilized from at least 2 months who had a mood disorder episode (depression, mania, hypomania or mixed) in the last year. * to be attended by a psychiatric specialist exclusion criteria: * inability to participate in the study * to have taken part in other study in the last 6 months

Keywords: bipolar disorders predictors of recurrence